Therapeutic Advances in Diabetic Nephropathy.

Sawaf, Hanny; Thomas, George; Taliercio, Jonathan J; Nakhoul, Georges; Vachharajani, Tushar J; Mehdi, Ali

Sawaf, Hanny; Thomas, George; Taliercio, Jonathan J; Nakhoul, Georges; Vachharajani, Tushar J; Mehdi, Ali.

Afiliação

Sawaf H; Department of Kidney Medicine, Glickman Urological & Kidney Institute, Cleveland Clinic Lerner College of Medicine, Cleveland Clinic, Cleveland, OH 44195, USA.
Thomas G; Department of Kidney Medicine, Glickman Urological & Kidney Institute, Cleveland Clinic Lerner College of Medicine, Cleveland Clinic, Cleveland, OH 44195, USA.
Taliercio JJ; Department of Kidney Medicine, Glickman Urological & Kidney Institute, Cleveland Clinic Lerner College of Medicine, Cleveland Clinic, Cleveland, OH 44195, USA.
Nakhoul G; Department of Kidney Medicine, Glickman Urological & Kidney Institute, Cleveland Clinic Lerner College of Medicine, Cleveland Clinic, Cleveland, OH 44195, USA.
Vachharajani TJ; Department of Kidney Medicine, Glickman Urological & Kidney Institute, Cleveland Clinic Lerner College of Medicine, Cleveland Clinic, Cleveland, OH 44195, USA.
Mehdi A; Department of Kidney Medicine, Glickman Urological & Kidney Institute, Cleveland Clinic Lerner College of Medicine, Cleveland Clinic, Cleveland, OH 44195, USA.

J Clin Med ; 11(2)2022 Jan 13.

Article em En | MEDLINE | ID: mdl-35054076

Palavras-chave

ACE inhibitors; ARB; MRA; SGLT2; diabetes; diabetic kidney disease; flozins; gliptins; nephropathy; therapeutics

Texto completo

Imprimir

XML

PubMed Links

Buscar no Google

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Tipo de estudo: Risk_factors_studies Idioma: En Revista: J Clin Med Ano de publicação: 2022 Tipo de documento: Article País de afiliação: Estados Unidos

Texto completo

Imprimir

XML

PubMed Links

Buscar no Google